Shanghai No.1 Pharmacy Stock Forecast for 2023 - 2025 - 2030
Updated on 05/17/2024
Shanghai No.1 Pharmacy Fair Value Forecast for 2023 - 2025 - 2030
In the last year, Shanghai No.1 Pharmacy's Price has fallen from ¥9.42 to ¥0.00 – a 100.00% decrease. In the next year, analysts expect Fair Value to reach ¥0.00 – an increase of 100.00%. For the next six years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 603939 Stock Forecast | Yifeng Pharmacy Chain | Buy |
18
|
¥44.98 | Buy/Sell | ¥47.67 | 20.28% |
| 603233 Stock Forecast | DaShenLin Pharmaceutical Group | Buy |
18
|
¥22.76 | Buy/Sell | ¥34.94 | 48.51% |
| 603883 Stock Forecast | LBX Pharmacy Chain Joint Stock | Outperform |
18
|
¥35.18 | Buy/Sell | ¥39.56 | 19.39% |
| 000028 Stock Forecast | China National Accord Medicine... | Outperform |
18
|
¥39.86 | Buy/Sell | ¥36.44 | 0.35% |
| 000503 Stock Forecast | China Reform Health Management... | - |
10
|
¥9.26 | Buy/Sell | ¥0.00 | -100.00% |
Shanghai No.1 Pharmacy Revenue Forecast for 2023 - 2025 - 2030
Shanghai No.1 Pharmacy's Revenue has increased by 14.66% In the last three years, going from ¥1.59B to ¥1.82B. In the next year, analysts expect Revenue to reach ¥1.89B – an increase of 4.04%. For the next seven years, the forecast is for Revenue to grow by 10.42%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 002727 Stock Forecast | Yixintang Pharmaceutical Group | Outperform |
16
|
¥22.74 | Buy/Sell | ¥29.95 | 2.07% |
| 000593 Stock Forecast | Delong Composite Energy Group | - |
11
|
¥5.50 | Buy/Sell | ¥14.44 | -100.00% |
| MDCE Stock Forecast | Medical Care Technologies | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
.jpg)
Shanghai No.1 Pharmacy Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Shanghai No.1 Pharmacy's Dividend per Share has grown, increasing from ¥0.10 to ¥0.13 – a growth of 30.00%. The next year looks promising for Shanghai No.1 Pharmacy, with analysts predicting Dividend per Share of ¥0.14 – an increase of 10.57%. Over the next seven years, experts anticipate that Shanghai No.1 Pharmacy's Dividend per Share will grow at a rate of 13.66%.
Shanghai No.1 Pharmacy EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Shanghai No.1 Pharmacy's EBITDA has gone down from ¥50.35M to ¥17.57M – a 65.10% drop. Next year, analysts are expecting EBITDA to reach ¥90.24M – an increase of 413.60%. Over the next seven years, the forecast is for EBITDA to grow by 10754.15%.
Shanghai No.1 Pharmacy EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Shanghai No.1 Pharmacy's EBIT has fallen from ¥42.99M to ¥11.41M – a 73.46% decrease. For next year, analysts predict EBIT of ¥87.33M, which would mean an increase of 665.39%. Over the next seven years, experts predict that Shanghai No.1 Pharmacy's EBIT will grow at a rate of 58863.51%.
Shanghai No.1 Pharmacy EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, Shanghai No.1 Pharmacy's EPS has fallen from ¥0.16 to ¥0.00 – a 100.00% decrease. In the next year, analysts expect EPS to reach ¥0.00 – an increase of 100.00%. For the next six years, the forecast is for EPS to grow by 100.00%.
Site Navigation
.jpg)